fullofdetermination
Greenlighter
- Joined
- Aug 22, 2026
- Messages
- 1
I'm trying to understand a reproducible acute effect from a standard fish-oil capsule and whether there is any pharmacokinetic or pharmacodynamic mechanism that could realistically fit the timing.
The fluvoxamine/diazepam interaction is important here. In a human pharmacokinetic study using 100–150 mg/day fluvoxamine, diazepam apparent oral clearance was reduced by approximately 65%, while mean diazepam half-life increased from about 51 to 118 hours. Elimination of its active metabolite N-desmethyldiazepam (nordiazepam) was also markedly inhibited.
I'm on 300 mg/day fluvoxamine, but I don't know of quantitative human PK data establishing exactly how much additional inhibition occurs at that dose, so I'm not assuming a specific half-life for my own case.
Study:https://pubmed.ncbi.nlm.nih.gov/7955810/
I occasionally take a single standard fish-oil capsule containing 180 mg EPA + 120 mg DHA (roughly 1 g total fish oil), usually around 7 hours after my diazepam dose.
Repeatedly, within roughly 3 hours, I experience a marked improvement in cognitive/sensory tolerance, most noticeably an increased ability to read for substantially longer.
It does not feel sedating. If anything, subjectively it feels like improved cognitive endurance.
I realize this is an N=1 observation and does not establish causality. Expectancy, coincidence, day-to-day variability, or another uncontrolled variable remain possible. I'm interested specifically in whether there is a biologically and quantitatively plausible mechanism that could fit the timing.
Søgaard et al. (2006) — GABA(A) receptor function is regulated by lipid bilayer elasticity
Nabekura et al. (1998) — Functional modulation of human recombinant GABA-A receptor by docosahexaenoic acid
Poling et al. (1996) — Docosahexaenoic acid block of neuronal voltage-gated K+ channels
Stillwell & Wassall (2003) — Docosahexaenoic acid: membrane properties of a unique fatty acid
I'm not taking these studies as evidence that an ordinary oral DHA dose can reproduce these effects acutely in humans.
In fact, that's one of the main things I'm trying to understand: whether oral exposure from only 120 mg DHA + 180 mg EPA could produce concentrations anywhere relevant to these experimental mechanisms within a few hours.
However, I don't want to assume that PK is irrelevant.
Could EPA/DHA acutely affect any of the following enough to alter effective diazepam/nordiazepam exposure?
A quantitative argument here would be particularly useful.
Possibilities I'm wondering about include:
The experimental literature shows that DHA can modulate some of these systems when directly available at sufficient concentrations.
What I cannot establish is whether an ordinary oral dose could generate relevant unesterified EPA/DHA concentrations in plasma or CNS tissue within ~3 hours.
That seems to be the critical missing bridge:
oral dose → absorption → circulating unesterified EPA/DHA → CNS exposure → local concentration at membrane/channel/receptor → functional effect
Is any part of that chain quantitatively plausible after such a small oral dose?
Could chronic benzodiazepine exposure, tolerance, and receptor adaptation make the functional effect of an otherwise small perturbation in membrane or ion-channel function more noticeable?
I'm not claiming that a plasma nordiazepam level of 1333 ng/mL establishes saturated GABA-A occupancy or any particular receptor state.
I'm mentioning the concentration mainly because, together with the markedly impaired elimination expected from the fluvoxamine interaction, it makes a large and rapid fluctuation in total benzodiazepine exposure seem unintuitive.
Given the dysautonomia, is there any plausible acute effect of EPA/DHA or downstream lipid mediators on:
that could improve cognitive/sensory tolerance within a few hours?
I'm mainly looking for mechanistic reasoning, quantitative PK arguments, or relevant literature, rather than treatment recommendations.
Context
- Diazepam: 10 mg/day, long-term use, with established tolerance.
- Fluvoxamine: 300 mg/day.
- My measured nordiazepam concentration was ~1333 ng/mL, above the usual therapeutic reference range.
- The benzodiazepine taper has not started yet.
- I also have dysautonomia with marked cognitive and sensory intolerance, so I'm not assuming the effect is necessarily GABAergic; autonomic, vascular, or other mechanisms would also be relevant.
The fluvoxamine/diazepam interaction is important here. In a human pharmacokinetic study using 100–150 mg/day fluvoxamine, diazepam apparent oral clearance was reduced by approximately 65%, while mean diazepam half-life increased from about 51 to 118 hours. Elimination of its active metabolite N-desmethyldiazepam (nordiazepam) was also markedly inhibited.
I'm on 300 mg/day fluvoxamine, but I don't know of quantitative human PK data establishing exactly how much additional inhibition occurs at that dose, so I'm not assuming a specific half-life for my own case.
Study:https://pubmed.ncbi.nlm.nih.gov/7955810/
I occasionally take a single standard fish-oil capsule containing 180 mg EPA + 120 mg DHA (roughly 1 g total fish oil), usually around 7 hours after my diazepam dose.
Repeatedly, within roughly 3 hours, I experience a marked improvement in cognitive/sensory tolerance, most noticeably an increased ability to read for substantially longer.
It does not feel sedating. If anything, subjectively it feels like improved cognitive endurance.
I realize this is an N=1 observation and does not establish causality. Expectancy, coincidence, day-to-day variability, or another uncontrolled variable remain possible. I'm interested specifically in whether there is a biologically and quantitatively plausible mechanism that could fit the timing.
Relevant literature / what led me to ask
I found several experimental papers showing that DHA/PUFAs can affect neuronal membrane proteins or GABA-A function:Søgaard et al. (2006) — GABA(A) receptor function is regulated by lipid bilayer elasticity
Nabekura et al. (1998) — Functional modulation of human recombinant GABA-A receptor by docosahexaenoic acid
Poling et al. (1996) — Docosahexaenoic acid block of neuronal voltage-gated K+ channels
Stillwell & Wassall (2003) — Docosahexaenoic acid: membrane properties of a unique fatty acid
I'm not taking these studies as evidence that an ordinary oral DHA dose can reproduce these effects acutely in humans.
In fact, that's one of the main things I'm trying to understand: whether oral exposure from only 120 mg DHA + 180 mg EPA could produce concentrations anywhere relevant to these experimental mechanisms within a few hours.
1. Could this plausibly be pharmacokinetic?
Given the prolonged disposition of diazepam/nordiazepam in this setting and my relatively high nordiazepam concentration, I find it difficult to see how one ordinary fish-oil capsule could substantially change total benzodiazepine concentrations within ~3 hours.However, I don't want to assume that PK is irrelevant.
Could EPA/DHA acutely affect any of the following enough to alter effective diazepam/nordiazepam exposure?
- CYP-mediated metabolism;
- plasma protein binding / free drug fraction;
- tissue distribution;
- intestinal absorption;
- transporters;
- or another PK process.
A quantitative argument here would be particularly useful.
2. Could there instead be a rapid pharmacodynamic effect?
If a meaningful PK interaction is implausible, are there pharmacodynamic mechanisms that could operate within hours, without requiring weeks of incorporation of DHA into neuronal membrane phospholipids?Possibilities I'm wondering about include:
- direct effects of circulating/unesterified fatty acids on ion channels or membrane proteins;
- acute GABA-A modulation;
- glutamatergic signaling;
- changes in membrane biophysics;
- neurosteroid signaling;
- rapidly generated lipid mediators;
- inflammatory signaling;
- autonomic or cerebrovascular effects.
The experimental literature shows that DHA can modulate some of these systems when directly available at sufficient concentrations.
What I cannot establish is whether an ordinary oral dose could generate relevant unesterified EPA/DHA concentrations in plasma or CNS tissue within ~3 hours.
That seems to be the critical missing bridge:
oral dose → absorption → circulating unesterified EPA/DHA → CNS exposure → local concentration at membrane/channel/receptor → functional effect
Is any part of that chain quantitatively plausible after such a small oral dose?
3. Does chronic benzodiazepine exposure/tolerance materially change the question?
Could chronic benzodiazepine exposure, tolerance, and receptor adaptation make the functional effect of an otherwise small perturbation in membrane or ion-channel function more noticeable?
I'm not claiming that a plasma nordiazepam level of 1333 ng/mL establishes saturated GABA-A occupancy or any particular receptor state.
I'm mentioning the concentration mainly because, together with the markedly impaired elimination expected from the fluvoxamine interaction, it makes a large and rapid fluctuation in total benzodiazepine exposure seem unintuitive.
4. Could dysautonomia provide a non-GABAergic explanation?
Given the dysautonomia, is there any plausible acute effect of EPA/DHA or downstream lipid mediators on:
- autonomic tone;
- cerebral blood flow;
- endothelial signaling;
- vascular function;
- or related physiology
that could improve cognitive/sensory tolerance within a few hours?
I'm mainly looking for mechanistic reasoning, quantitative PK arguments, or relevant literature, rather than treatment recommendations.
